Achiko AG – Publication of the annual report and the financial statements Annual financial statements 2021 by June 20, 2022

Achiko AG – Release of Annual Report and Financial Statements 2021 financial statements by June 20, 2022

Zurich, June 10, 2022: Ad hoc notification pursuant to Art. 53 KR Achiko Inc (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and accounts for the year 2021 no later than June 20, 2022. As a company listed on the SIX, Achiko is required to publish its annual report together with the financial statements within four months of the balance sheet date. Due to the Covid-19 pandemic, the recruitment of staff and training under difficult conditions as a result of the measures taken by several countries took a lot of management capacity, therefore the publication of the annual report and financial statements as of December 31, 2021 will take place in June 2022. Achiko has submitted a request to the SIX Exchange Regulation (SER) for an exemption for the publication of the 2021 annual report and financial statements. On April 28, 2022, SER granted Achiko the requested extension. Achiko submitted a second application to SER for an extension of the deadline for the publication of the 2021 annual report and financial statements. On May 30, 2022, SER granted Achiko the second extension. On June 3, 2022, the SER granted Achiko the third extension. Achiko applied to SER for a fourth extension of the deadline for the publication of the annual report and financial statements for 2021. On June 10, 2022, SER granted Achiko the fourth extension of the deadline.

The delay is due to the factors previously mentioned, including the business continuity in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative burden, particularly related to audit reconciliation documentation.

In advance of the release of the audited financial statements, the Company reports the following unaudited financial figures for the year ended December 31, 2021 (with comparisons to 2020):

2021 (USD000s) 2020 (USD000s)

SALES 63 2,806

EBITDA LOSS 8,295 14,217

OPERATING LOSS 9,396 14,069

CURRENT LIABILITIES 6,144 5,496

TOTAL ASSETS 1,914 1,772

SHAREHOLDER EQUITY (4,647) (4,052)

In a previous announcement dated May 19, 2022, the Company reported an unaudited Adjusted EBITDA loss of USD 5.258 million and noted that the adjustments to equity based items are ongoing. The final unaudited stock-based payments (stock options, interest, financing costs, etc.) are $2.711 million and include an interest component of $0.835 million. The difference between the previously reported adjusted EBITDA loss and the final unaudited EBITDA loss of $8.295 million is due to: (1) charges of $0.713 million related to a Swiss subsidiary and the recovery of accounting records; (2) the re-inclusion of $0.500 million in directors’ fees (the directors’ fees and advisory board fees are substantially outstanding, unpaid and majority subordinate); (3) $1.876 million in interest-free stock-based payments; and (4) other miscellaneous customizations.

Overall, operating losses in 2021 compared to the prior year reflect continued investment in the commercialization of AptameX, in a challenging operating environment and significant cost reductions in the second half of 2021. Given the Company’s position at year-end, the focus was on commercializing AptameX. To achieve this goal, the Company successfully reported, after the period end, AptameX in vivo performance results, indicating a highly sensitive and highly specific test at low viral loads for Covid-19, distribution and marketing agreements with the largest Islamic Organization of the World, Nahdlatul Ulama in Indonesia, updated manufacturing contracts with manufacturing partner Indofarma in Indonesia, obtaining a CE Mark allowing the Company to sell AptameX in Europe, and accepting $1.25 million in funding .in a range of equity and debt instruments.

As requested by SER, Achiko hereby reprints paragraph 1 of the relevant decision of SER:

“The application for an exception by Achiko (issuer) dated June 10, 2022, with which a fourth extension of the deadline for the publication of the 2021 annual report and its filing with SIX Exchange Regulation AG by June 20, 2022 at the latest is requested, subject to the following reservation (lit. a) and granted under the following conditions (lit. b):

1. SIX Exchange Regulation AG reserves the right to suspend trading in the issuer’s registered shares if the 2021 Annual Report does not comply with the provisions on ad hoc publicity (Art. 53 Listing Rules [KR] in connection with the Ad Hoc Publicity Policy [DAH]) and submitted to SIX Exchange AG by Monday, June 20, 2022, 11:59 p.m. CET at the latest.
2. Achiko is obliged to publish a notice of this decision in accordance with the provisions on ad hoc publicity (Art. 53 LR in conjunction with the RLAhP) no later than Friday, June 10, 2022, 11:59 p.m. CET. The notice must contain:
   • the unchanged reproduction of the wording of Section I. of this decision in a prominent position;
   • the reasons for the issuer’s request for a fourth extension of the deadline for the publication of the 2021 annual report and its filing with SIX Exchange Regulation AG.
   • the updated unaudited key figures such as net sales, EBITDA, EBIT, profit/loss, total assets, equity, etc. for the 2021 annual result.»

The date of the next ordinary general meeting will be announced in due course once the Company has published its annual report and accounts for the year 2021.

ABOUT ACHIKO AG

Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) develops breakthrough diagnostic solutions that put people first. The company’s flagship product is a fast, reliable Covid-19 test with a companion app that offers an easy-to-use digital health passport. The test and accompanying app were launched in Indonesia in mid-2021, and in May 2022 AptameX received the CE mark from the European Union.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXTM, and companion health apps through its digital mobile health technology division, Teman SehatTM. The AptameX DNA aptamer tests can be chemically manufactured quickly, are inexpensive and have great potential for the diagnosis of various diseases. Through the use of AptameX and Teman Sehat, Achiko aims to offer fast, accurate and affordable diagnostic tests for a range of pathogenic diseases and therapeutic indications in the rapidly evolving field of healthcare diagnostics.

Achiko’s headquarters are in Zurich; the company has offices in Hong Kong, Jakarta, Seoul and Singapore.

Media contacts:

ACHIKO AG

Investor Relations

E [email protected]

Switzerland & Global

Marcus Balogh

Farner Consulting Ltd.

E: [email protected]

T: +41 44 266 67 67

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained in as a result of new information, future events or otherwise.